Through analyses of TMAs and the TCGA database, DYRK2 was found to be downregulated in CRC tumor tissues relative to healthy colorectal tissue samples, with its downregulation being associated with patient clinicopathological characteristics. This evidence concerns the gene DYRK2 and colorectal carcinoma.